Biodistribution and radiation dosimetry of 18F-CP-18, a potential apoptosis imaging agent, as determined from PET/CT scans in healthy volunteers

Journal of Nuclear Medicine

Volumn 54, Issue 12, 2013, Pages 2087-2092

  Doss, Mohan ^a   Kolb, Hartmuth C ^b   Walsh, Joseph C ^b   Mocharla, Vani ^b   Fan, Hong ^b   Chaudhary, Ashok ^b   Zhu, Zhihong ^b   Alpaugh, R Katherine ^a   Lango, Miriam N ^a   Yu, Jian Q ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b SIEMENS CORPORATE RESEARCH   (United States)

Author keywords

Apoptosis marker; Biodistribution; Internal dosimetry; PET

Indexed keywords

18F CP 18; FLUORINE 18; TRACER; UNCLASSIFIED DRUG; CP 18 COMPOUND; CP-18 COMPOUND; DIAGNOSTIC AGENT; GLYCOPEPTIDE; TRIAZOLE DERIVATIVE;

ADULT; APOPTOSIS; ARTICLE; BLADDER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSE RESPONSE; DOSIMETRY; DRUG DISTRIBUTION; FEMALE; HALF LIFE TIME; HEART; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY; KIDNEY CLEARANCE; LIVER; MALE; NORMAL HUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DOSE DISTRIBUTION; RADIOISOTOPE DISTRIBUTION; WHOLE BODY PET; 18F-CP-18; APOPTOSIS MARKER; BIODISTRIBUTION; CLINICAL TRIAL; INTERNAL DOSIMETRY; MIDDLE AGED; MULTIMODAL IMAGING; PET; POSITRON EMISSION TOMOGRAPHY; RADIOMETRY; TISSUE DISTRIBUTION; DIAGNOSTIC USE;

18F-CP-18; APOPTOSIS MARKER; BIODISTRIBUTION; INTERNAL DOSIMETRY; PET;

ADULT; APOPTOSIS; FEMALE; GLYCOPEPTIDES; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOMETRY; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED; TRIAZOLES;

EID: 84893441437     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.119800     Document Type: Article

References (36)

1. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495-516.
2. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996;379:88-91.
3. Kunz M, Ibrahim SM. Molecular responses to hypoxia in tumor cells. Mol Cancer. 2003;2:23.
4. Reshef A, Shirvan A, Waterhouse RN, et al. Molecular imaging of neurovascular cell death in experimental cerebral stroke by PET. J Nucl Med. 2008;49:1520-1528.
5. Cohen A, Shirvan A, Levin G, Grimberg H, Reshef A, Ziv I. From the Gla domain to a novel small-molecule detector of apoptosis. Cell Res. 2009;19:625-637.
6. Höglund J, Shirvan A, Antoni G, et al. 18F-ML-10, a PET tracer for apoptosis: first human study. J Nucl Med. 2011;52:720-725.
7. Wang F, Fang W, Zhang MR, et al. Evaluation of chemotherapy response in VX2 rabbit lung cancer with 18F-labeled C2A domain of synaptotagmin I. J Nucl Med. 2011;52:592-599.
8. Grierson JR, Yagle KJ, Eary JF, et al. Production of [F-18]fluoroannexin for imaging apoptosis with PET. Bioconjug Chem. 2004;15:373-379.
9. Toretsky J, Levenson A, Weinberg IN, Tait JF, Uren A, Mease RC. Preparation of F-18 labeled annexin V: a potential PET radiopharmaceutical for imaging cell death. Nucl Med Biol. 2004;31:747-752.
10. Yagle KJ, Eary JF, Tait JF, et al. Evaluation of 18F-annexin V as a PET imaging agent in an animal model of apoptosis. J Nucl Med. 2005;46:658-666.
11. Madar I, Ravert H, Nelkin B, et al. Characterization of membrane potentialdependent uptake of the novel PET tracer 18F-fluorobenzyl triphenylphosphonium cation. Eur J Nucl Med Mol Imaging. 2007;34:2057-2065.
12. Madar I, Huang Y, Ravert H, et al. Detection and quantification of the evolution dynamics of apoptosis using the PET voltage sensor 18F-fluorobenzyl triphenyl phosphonium. J Nucl Med. 2009;50:774-780.
13. Reshef A, Shirvan A, Akselrod-Ballin A, Wall A, Ziv I. Small-molecule biomarkers for clinical PET imaging of apoptosis. J Nucl Med. 2010;51:837-840.
14. Faust A, Wagner S, Law MP, et al. The nonpeptidyl caspase binding radioligand (S)-1-(4-(2-[18F]Fluoroethoxy)-benzyl)-5-[1-(2- methoxymethylpyrrolidinyl)sulfonyl] isatin ([18F]CbR) as potential positron emission tomography-compatible apoptosis imaging agent. Q J Nucl Med Mol Imaging. 2007;51:67-73.
15. Smith G, Glaser M, Perumal M, et al. Design, synthesis, and biological characterization of a caspase 3/7 selective isatin labeled with 2-[18F]fluoroethylazide. J Med Chem. 2008;51:8057-8067.
16. Nguyen QD, Smith G, Glaser M, Perumal M, Arstad E, Aboagye EO. Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase- 3/7 specific [18F]-labeled isatin sulfonamide. Proc Natl Acad Sci USA. 2009; 106:16375-16380.
17. Podichetty AK, Faust A, Kopka K, et al. Fluorinated isatin derivatives. Part 1: synthesis of new N-substituted (S)-5-[1-(2-methoxymethylpyrrolidinyl) sulfonyl] isatins as potent caspase-3 and -7 inhibitors. Bioorg Med Chem. 2009;17:2680-2688.
18. Podichetty AK, Wagner S, Schroer S, et al. Fluorinated isatin derivatives. Part 2. New N-substituted 5-pyrrolidinylsulfonyl isatins as potential tools for molecular imaging of caspases in apoptosis. J Med Chem. 2009;52:3484-3495.
19. Zhou D, Chu W, Chen D, et al. [18F]- and [11C]-labelled N-benzyl-isatin sulfonamide analogues as PET tracers for apoptosis: synthesis, radiolabeling mechanism, and in vivo imaging of apoptosis in Fas-treated mice using [11C]WC-98. Org Biomol Chem. 2009;7:1337-1348.
20. Nguyen QD, Challapalli A, Smith G, Fortt R, Aboagye EO. Imaging apoptosis with positron emission tomography: 'bench to bedside' development of the caspase-3/7 specific radiotracer [18F]ICMT-11. Eur J Cancer. 2012;48:432-440.
21. Zhou D, ChuW, Rothfuss J, et al. Synthesis, radiolabeling, and in vivo evaluation of an 18F-labeled isatin analog for imaging caspase-3 activation in apoptosis. Bioorg Med Chem Lett. 2006;16:5041-5046.
22. Niu G, Chen X. Apoptosis imaging: beyond annexin V. J Nucl Med. 2010;51: 1659-1662.
23. Talanian RV, Quinlan C, Trautz S, et al. Substrate specificities of caspase family proteases. J Biol Chem. 1997;272:9677-9682.
24. Walsh JC, Kolb HC. Applications of click chemistry in radiopharmaceutical development. Chimia (Aarau). 2010;64:29-33.
25. Marik J, Sutcliffe JL. Click for PET: rapid preparation of [18F]fluoropeptides using CuI catalyzed 1,3-dipolar cycloaddition. Tetrahedron Lett. 2006;47:6681-6684.
26. Mamat C, Ramenda T, Wuest FR. Recent applications of click chemistry for the synthesis of radiotracers for molecular imaging. Mini Rev Org Chem. 2009;6:21-34.
27. Su H, Chen G, Gangadharmath U, et al. Evaluation of [18F]-CP18 as a PET imaging tracer for apoptosis. Mol Imaging Biol. May 17, 2013 [Epub ahead of print].
28. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
29. Food and Drug Administration. Guidance for Industry and Researchers. The Radioactive Drug Research Committee: Human ResearchWithout An Investigational New Drug Application. August 2010. Available at: http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM163892.pdf. Accessed September 24, 2013.
30. Stabin M, Stubbs J, Toohey R. Radiation Dose Estimates for Radiopharmaceuticals, NUREG/CR-6345. April 1996. Available at: http://www.nrc.gov/reading-rm/doccollections/ nuregs/contract/cr6345/cr6345.pdf. Accessed September 24, 2013.
31. Krajewska M, Wang HG, Krajewski S, et al. Immunohistochemical analysis of in vivo patterns of expression of CPP32 (caspase-3), a cell death protease. Cancer Res. 1997;57:1605-1613.
32. Kurihara H, Yang DJ, Cristofanilli M, et al. Imaging and dosimetry of 99mTc EC annexin V: preliminary clinical study targeting apoptosis in breast tumors. Appl Radiat Isot. 2008;66:1175-1182.
33. Fischer U, Schulze-Osthoff K. Apoptosis-based therapies and drug targets. Cell Death Differ. 2005;12(suppl 1):942-961.
34. Gillies RJ, Verduzco D, Gatenby RA. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer. 2012;12:487-493.
35. Jendrossek V. The intrinsic apoptosis pathways as a target in anticancer therapy. Curr Pharm Biotechnol. 2012;13:1426-1438.
36. Sayers TJ. Targeting the extrinsic apoptosis signaling pathway for cancer therapy. Cancer Immunol Immunother. 2011;60:1173-1180.